Copanlisib Mass Balance Study

Phase 1

Completed

• Conditions: Healthy Volunteers
• Interventions: Drug: Copanlisib (BAY80-6946)

• Registration Number: NCT02119221
• Lead Sponsor: Bayer

Brief Summary

The study aims to provide understanding of the relative relevance of the different excretion pathways of Copanlisib in humans, as well as to characterize its metabolite profile.

Detailed Description

Not available

Study Timeline

• Study Start: 2014-02
• Primary Completion: 2014-04
• Study First Submitted: 2014-04-17
• Study First Submitted QC: 2014-04-17
• Study First Posted: 2014-04-21
• Status Verified: 2014-10
• Study Completion: 2014-10
• Last Update Submitted: 2014-10-27
• Last Update Posted: 2014-10-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 6

Inclusion Criteria

• Healthy male subject
• Age: 45 to 65 years
• Body weight greater or equal to 60 kg and body mass index (BMI): above/equal 18 and below/equal 30 kg/m²

Read More

Exclusion Criteria

• Regular use of medicines
• Known recent (last 2 years) abuse of recreational drugs, suspicion of drug or alcohol abuse, or positive results of the drug and alcohol screen tests at screening or baseline
• Use of strong inhibitors of cytochrome P450 (CYP)3A4, as well as use of St John's Wort or strong inducers of CYP3A4 prohibited from 14 days before the administration of study drug until discharge from the clinic
• Smoking
• Average intake of more than 24 units of alcohol per week; Regular daily consumption of more than 1 L of methylxanthine-containing beverages
• Any condition, which may result in longer than usual retention of urine or feces in the body, such as pronounced (less than one defecation in 2 days) constipation or symptomatic prostatic hypertrophy.
• Participation in another mass balance study with a radiation burden > 0.1 mSv in the period of 1 year before screening

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
[14C]Copanlisib	Copanlisib (BAY80-6946)	-

Primary Outcome Measures

Name	Time	Method
Metabolite profile in urine	Multiple time points up to 336 hours
Pharmacokinetics of copanlisib in plasma by area under the measured matrix concentration versus time curve from the first time point (t=0) extrapolated to infinity (AUC)	Multiple time points up to 336 hours
Pharmacokinetics of total radioactivity in whole blood by Cmax	Multiple time points up to 336 hours
Pharmacokinetics of total radioactivity in whole blood by AUC(0-tlast)	Multiple time points up to 336 hours
Pharmacokinetics of copanlisib in plasma by maximum concentration (Cmax)	Multiple time points up to 336 hours
Pharmacokinetics of total radioactivity in whole blood by AUC	Multiple time points up to 336 hours
Metabolite profile in feces	Multiple time points up to 336 hours
Pharmacokinetics of copanlisib in plasma by area under the measured matrix concentration versus time curve to the last data point above the lower limit of quantitation (AUC(0-tlast))	Multiple time points up to 336 hours
Pharmacokinetics of total radioactivity in plasma by Cmax	Multiple time points up to 336 hours
Pharmacokinetics of total radioactivity in plasma by AUC	Multiple time points up to 336 hours
Pharmacokinetics of total radioactivity in plasma by AUC(0-tlast)	Multiple time points up to 336 hours
Radioactivity excreted in urine as a percentage of the dose (AE,ur)	Multiple time points up to 336 hours
Radioactivity excreted in feces as a percentage of the dose (AE,fec)	Multiple time points up to 336 hours
Metabolite profile in plasma	Multiple time points up to 336 hours

Secondary Outcome Measures

Name	Time	Method
Number of participants with adverse events as a measure of safety and tolerability	Until 30 days after study drug administration